The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

The annual New York Sportsman’s Expo returns to the Exposition Center at the NYS Fairgrounds this weekend, Jan. 24-26. Hours are 12-7 Friday, 9-7 Saturday, and 9-5 Sunday. You can buy tickets ...

If you buy something, we may earn an affiliate commission. Tailored jackets are a keystone species in the menswear ecosystem, but there’s a lot more to them than meets the eye. For one thing ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...